Xcout Intel
Renibus Therapeutics, Inc.
Renibus Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Southlake, Texas, dedicated to transforming outcomes in specialty therapeutics and disease treatments.
Subscribe to see Renibus Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Renibus Therapeutics, Inc. at a glance
Renibus Therapeutics, Inc. is a drug discovery company headquartered in United States. Its most recent funding round, Series B, raised $72M in September 2023. Xcout tracks 8 named people at Renibus Therapeutics, Inc., including D Jeffrey Keyser (Chief Executive Officer).
Renibus Therapeutics, Inc. leadership
- D Jeffrey KeyserChief Executive Officer
- D. Jeff KeyserPresident and CEO
- Jamie A. DonadioChief Financial Officer
- Asha RamdasChief Technical Officer
- Bhupinder SinghChief Medical Officer
- HENRIK RASMUSSENChairman
2 more named people on record for Renibus Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Renibus Therapeutics, Inc. funding rounds
The 5 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $72M | — | |
| SEC Form D filing | $110.9M | — | |
| SEC Form D filing | $23.4M | — | |
| SEC Form D filing | $3.4M | — | |
| — | $19.8M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Renibus Therapeutics, Inc. competitors
A few of Renibus Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Alebund Pharmaceuticals is a biopharmaceutical company founded in early 2018 in Shanghai, China, with operations also in Yangzhou City, focusing on the discovery and development of treatments for kidney disease.
Rege Nephro Co., Ltd. is a biotechnology company headquartered at Kyoto University in Kyoto, Japan. The company engages in medical-pharmaceutical collaborative research and advanced therapeutic development for kidney and regenerative medicine.
Renasis Bio Ltd. is a stealth-mode private company headquartered in Rehovot, Israel, established in 2025. The firm is developing an AI-driven drug discovery platform focused on RNA-targeting small molecules to advance RNA druggability.
Astria Therapeutics, Inc. is a public biopharmaceutical company headquartered in Boston, Massachusetts, dedicated to developing life-changing therapies for patients.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. The company discovers and develops Anticalin-based drugs designed to address significant medical needs.
Orbital Therapeutics is a biotechnology company developing RNA medicines, with a focus on engineered circular RNA and delivery technologies. Its programs are intended to address diseases that may benefit from durable, programmable protein expression, serving patients and healthcare providers through potential therapeutic products.
Get Renibus Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Renibus Therapeutics, Inc. in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 6 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access